Jun 30
Implantable Marker Recall: Hologic Removes BioZorb 3D Bioabsorbable Markers due to Risk for Patient Complications
Medical Devices
November 12, 2025 - FDA Commissioner and subject matter experts from the Center for Drug Evaluation and Research discussed the agency's recent announcement regarding the removal of the "black box warning" for hormone replacement therapy.
View Recording
We know you're busy! The easiest way to keep up with us is to subscribe to our weekly e-newsletter.
You'll get the latest announcements, regulations, and upcoming events delivered to your email inbox every Monday.
Health professionals, consumers and patients can voluntarily report observed or suspected adverse events for human medical products to FDA. Voluntary reporting can help FDA identify unknown risk for approved medical products.
Learn MoreJun 30
Medical Devices
Jun 26
Medical Devices
Jun 17
Medical Devices
Recently FDA leadership held a roundtable discussion with 15 dedicated rare disease leaders.
FDA continues to prioritize the speed and efficiency with which generic drugs are regulated, balancing the need for minimizing risk and ensuring access.
For five decades, the 1976 Amendments have served as the foundation of a regulatory framework designed to protect patients.
FDA MedWatch Safety Information
You know the moment it happens.
Follow @FDAMedWatch